Content area

|
|

Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

Appen ImmunTox kan downloades gratis til både iOS og Android.
Forfatter(e)
Maria Kondrup1, Louise Raunkilde1, Inge Marie Svane2, Henrik Schmidt3 & Lars Bastholt4 1) Onkologisk Afdeling, Odense Universitetshospital 2) Onkologisk Afdeling, Herlev Hospital 3) Onkologisk Afdeling, Aarhus Universitetshospital 4) Onkologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2017;179:V05170365
Reference: 
Ugeskr Læger 2017;179:V05170365
Blad nummer: 
Sidetal: 
2-6
Immunotherapy is cancer treatment with a novel side-effect profile
Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors – anti-cyto-toxic T-lymphocyte-associated-4 antibodies and anti-program­med cell death 1/anti-programmed cell death ligand 1 anti­bodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque­lae. We provide a detailed overview of irAEs and recom­mendations for treatment according to established guidelines.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Lars Erik Larsen | 19/02
3 kommentarer
af Svend Ovesen | 18/02
1 Kommentar
af Peter Gammelgaard Petersen | 18/02
1 Kommentar
af Steen Frobenius | 17/02
2 kommentarer
af Lawkesh Vimal Hurry | 16/02
3 kommentarer